Literature DB >> 34473060

Understanding patterns of HIV multi-drug resistance through models of temporal and spatial drug heterogeneity.

Alison F Feder1,2, Kristin N Harper3, Chanson J Brumme4,5, Pleuni S Pennings6.   

Abstract

Triple-drug therapies have transformed HIV from a fatal condition to a chronic one. These therapies should prevent HIV drug resistance evolution, because one or more drugs suppress any partially resistant viruses. In practice, such therapies drastically reduced, but did not eliminate, resistance evolution. In this article, we reanalyze published data from an evolutionary perspective and demonstrate several intriguing patterns about HIV resistance evolution - resistance evolves (1) even after years on successful therapy, (2) sequentially, often via one mutation at a time and (3) in a partially predictable order. We describe how these observations might emerge under two models of HIV drugs varying in space or time. Despite decades of work in this area, much opportunity remains to create models with realistic parameters for three drugs, and to match model outcomes to resistance rates and genetic patterns from individuals on triple-drug therapy. Further, lessons from HIV may inform other systems.
© 2021, Feder et al.

Entities:  

Keywords:  Drug resistance; HIV; evolution; evolutionary biology; genetics; genomics; spatial heterogeneity; temporal heterogeneity; virus

Mesh:

Substances:

Year:  2021        PMID: 34473060      PMCID: PMC8412921          DOI: 10.7554/eLife.69032

Source DB:  PubMed          Journal:  Elife        ISSN: 2050-084X            Impact factor:   8.140


  83 in total

Review 1.  Adherence-resistance relationships to combination HIV antiretroviral therapy.

Authors:  David R Bangsberg; Deanna L Kroetz; Steven G Deeks
Journal:  Curr HIV/AIDS Rep       Date:  2007-05       Impact factor: 5.071

2.  Derivation and properties of Michaelis-Menten type and Hill type equations for reference ligands.

Authors:  T C Chou
Journal:  J Theor Biol       Date:  1976-07-07       Impact factor: 2.691

3.  Mass spectrometry imaging reveals heterogeneous efavirenz distribution within putative HIV reservoirs.

Authors:  Corbin G Thompson; Mark T Bokhart; Craig Sykes; Lourdes Adamson; Yuri Fedoriw; Paul A Luciw; David C Muddiman; Angela D M Kashuba; Elias P Rosen
Journal:  Antimicrob Agents Chemother       Date:  2015-03-02       Impact factor: 5.191

4.  Longitudinal trends of HIV drug resistance in a large Canadian cohort, 1996-2016.

Authors:  G Rocheleau; C J Brumme; J Shoveller; V D Lima; P R Harrigan
Journal:  Clin Microbiol Infect       Date:  2017-06-23       Impact factor: 8.067

5.  A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.

Authors:  S M Hammer; K E Squires; M D Hughes; J M Grimes; L M Demeter; J S Currier; J J Eron; J E Feinberg; H H Balfour; L R Deyton; J A Chodakewitz; M A Fischl
Journal:  N Engl J Med       Date:  1997-09-11       Impact factor: 91.245

6.  Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party.

Authors:  J J Eron; S L Benoit; J Jemsek; R D MacArthur; J Santana; J B Quinn; D R Kuritzkes; M A Fallon; M Rubin
Journal:  N Engl J Med       Date:  1995-12-21       Impact factor: 91.245

7.  Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system.

Authors:  Scott Letendre; Jennifer Marquie-Beck; Edmund Capparelli; Brookie Best; David Clifford; Ann C Collier; Benjamin B Gelman; Justin C McArthur; J Allen McCutchan; Susan Morgello; David Simpson; Igor Grant; Ronald J Ellis
Journal:  Arch Neurol       Date:  2008-01

8.  Viremia, resuppression, and time to resistance in human immunodeficiency virus (HIV) subtype C during first-line antiretroviral therapy in South Africa.

Authors:  Christopher J Hoffmann; Salome Charalambous; John Sim; Joanna Ledwaba; Graham Schwikkard; Richard E Chaisson; Katherine L Fielding; Gavin J Churchyard; Lynn Morris; Alison D Grant
Journal:  Clin Infect Dis       Date:  2009-12-15       Impact factor: 9.079

9.  Human Immunodeficiency Virus Drug Resistance: 2018 Recommendations of the International Antiviral Society-USA Panel.

Authors:  Huldrych F Günthard; Vincent Calvez; Roger Paredes; Deenan Pillay; Robert W Shafer; Annemarie M Wensing; Donna M Jacobsen; Douglas D Richman
Journal:  Clin Infect Dis       Date:  2019-01-07       Impact factor: 9.079

10.  A model of HIV drug resistance driven by heterogeneities in host immunity and adherence patterns.

Authors:  Anna Bershteyn; Philip A Eckhoff
Journal:  BMC Syst Biol       Date:  2013-02-04
View more
  3 in total

1.  Antiretroviral Imprints and Genomic Plasticity of HIV-1 pol in Non-clade B: Implications for Treatment.

Authors:  Jude S Bimela; Aubin J Nanfack; Pengpeng Yang; Shaoxing Dai; Xiang-Peng Kong; Judith N Torimiro; Ralf Duerr
Journal:  Front Microbiol       Date:  2022-02-09       Impact factor: 5.640

2.  Influence of seasonal and geographic variation on the anti-HSV-1 properties and chlorogenic acids content of Helichrysum aureonitens Sch. Bip.

Authors:  Wilson Bamise Adeosun; Garland K More; Paul Steenkamp; Gerhard Prinsloo
Journal:  Front Mol Biosci       Date:  2022-08-25

3.  Subgenomic sequence analysis reveals emergence of new circulating recombinant forms of HIV-1 in Pakistan.

Authors:  Maria Zahid; Saeed Khan; Muhammad Asif Qureshi; Yasir Raza
Journal:  Pak J Med Sci       Date:  2022 Sep-Oct       Impact factor: 2.340

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.